| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01562886 | HIV | Drug: Rilpivirine | Imperial College London|Janssen-Cilag Ltd. | Phase 1 | 2012-03-01 | 2014-05-19 |
| NCT02494986 | Human Immunodeficiency Virus Type 1 | Drug: Rilpivirine | Janssen Sciences Ireland UC | Phase 2 | 2015-07-01 | 2016-08-25 |
| NCT02547870 | Human Immunodeficiency Virus Type 1 | Drug: Rilpivirine (RPV)|Drug: Rilpivirine Long-Acting Parenteral Formulation (RPVA)|Drug: Aged RPVA | Janssen Infectious Diseases BVBA | Phase 1 | 2015-08-01 | 2016-07-05 |
| NCT02404233 | HIV Positive | Drug: darunavir/cobicistat|Drug: rilpivirine | Therapeutic Concepts|Janssen Scientific Affairs, LLC | Phase 4 | 2015-03-01 | 2015-03-30 |
| NCT01719614 | Healthy Participants | Drug: Metformin|Drug: Rilpivirine | Janssen R&D Ireland | Phase 1 | 2012-10-01 | 2014-03-05 |
| NCT02530060 | Healthy | Drug: Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC | Janssen Pharmaceutical K.K. | Phase 4 | 2015-08-01 | 2016-12-30 |
| NCT01615614 | Healthy | Drug: Rilpivirine|Drug: Rifabutin | Janssen R&D Ireland | Phase 1 | 2012-04-01 | 2014-03-27 |
| NCT03033368 | HIV | Drug: Rilpivirine | Mahidol University|amfAR, The Foundation for AIDS Research | Phase 2|Phase 3 | 2015-07-01 | 2017-01-24 |
| NCT01692470 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Drug: No intervention | Janssen Pharmaceutica | Phase 4 | 2013-06-01 | 2015-11-30 |
| NCT01585038 | Cardiovascular Disease | Drug: Efavirenz|Drug: Rilpivirine | Indiana University|Janssen Services, LLC | Phase 4 | 2012-07-01 | 2015-07-27 |
| NCT02165202 | Human Immunodeficiency Virus (HIV) | Drug: Rilpivirine|Drug: Placebo | PATH|Bill and Melinda Gates Foundation|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH) | Phase 2 | 2014-10-01 | 2016-03-14 |
| NCT01268839 | HIV | Drug: TMC278|Drug: TMC278|Drug: Efavirenz | Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | Phase 1 | 2010-01-01 | 2013-09-02 |
| NCT02104700 | HIV | Drug: Rilpivirine/Emtricitabine/Tenofovir | Philip Grant|Rwanda Biomedical Center|Gilead Sciences|Stanford University | Phase 2|Phase 3 | 2014-04-01 | 2015-07-15 |
| NCT02561936 | Healthy | Drug: Rilpivirine Oral Tablet|Drug: Rilpivirine formulation G007|Drug: Rilpivirine formulation G009-01|Drug: Rilpivirine formulation G002|Dietary Supplement: Standardized Breakfast | Janssen Sciences Ireland UC | Phase 1 | 2015-10-01 | 2016-06-09 |
| NCT01049932 | HIV Infections | Drug: TMC278LA | St Stephens Aids Trust | Phase 1|Phase 2 | 2010-03-01 | 2010-08-13 |
| NCT01656018 | Healthy | Drug: TMC278, Long acting (LA) | Janssen Research & Development, LLC | Phase 1 | 2012-11-01 | 2016-04-06 |
| NCT01266902 | HIV-1 Infection | Drug: Rilpivirine | Janssen R&D Ireland | Phase 3 | 2011-02-25 | 2017-03-14 |
| NCT00799864 | Human Immuno Deficiency (HIV) Infection | Drug: Rilpivirine|Drug: Zidovudine|Drug: Abacavir|Drug: Tenofovir disoproxil fumarate|Drug: Lamivudine|Drug: Emtricitabine | Janssen Sciences Ireland UC | Phase 2 | 2011-01-07 | 2017-03-21 |
| NCT01975012 | HIV Infections | Drug: Rilpivirine | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Mental Health (NIMH) | Phase 1|Phase 2 | 2014-09-01 | 2015-08-31 |
| NCT01804244 | Healthy | Drug: TMC278 | Janssen Pharmaceutical K.K. | Phase 4 | 2013-03-01 | 2014-03-18 |
